Romark is currently conducting a U.S. Phase II trial with nitazoxanide plus standard of care in patients with hepatitis C genotype 1 who were previously treated with interferon. The Company also plans to initiate a Phase II trial in treatment naive patients early in 2008.
About Hepatitis C
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV), a virus spread through direct contact with the blood of infected people. Chronic HCV infection may cause liver cirrhosis or hepatocellular carcinoma. An estimated 3.2 million people in the U.S. are chronically infected by hepatitis C virus. Globally, an estimated 170 million people are chronically infected, with three to four million persons newly infected each year, according to the World Health Organization.
About Romark Laboratories
Romark Laboratories, L.C. (http://www.romark.com) is a privately-owned biotechnology company committed to the discovery and development of innovative new small molecules for treating infectious diseases, cancers, and autoimmune diseases.
Alinia (nitazoxanide) is indicated in the United States for treatment
of diarrhea caused by Cryptosporidium parvum or Giardia lamblia in patients
1 year of age and older. Alinia has not been shown to be superior to
placebo for the treatment of diarrhea caused by Cryptosporidium parvum in
HIV-infected or immunodeficient patients. The most common adverse events
|SOURCE Romark Laboratories|
Copyright©2007 PR Newswire.
All rights reserved